Bristol-Myers Squibb AOCI increased by 10.1% to -$1.37B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 3.8%, from -$1.42B to -$1.37B. Over 5 years (FY 2020 to FY 2025), AOCI shows an upward trend with a -3.7% CAGR.
Fluctuations often reflect macroeconomic factors like currency volatility or interest rate changes rather than operational performance.
Accumulated other comprehensive income (AOCI) includes cumulative gains and losses that are excluded from net income, su...
Multinational pharmaceutical companies often show volatility here due to extensive global operations and exposure to foreign exchange rates.
aoci| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | -$1.52B | -$1.42B | -$1.27B | -$1.23B | -$992.00M | -$841.00M | -$1.28B | -$1.37B | -$1.39B | -$1.29B | -$1.55B | -$1.40B | -$1.46B | -$1.47B | -$1.24B | -$1.42B | -$1.55B | -$1.51B | -$1.52B | -$1.37B |
| QoQ Change | — | +6.2% | +11.0% | +3.1% | +19.3% | +15.2% | -52.3% | -6.8% | -1.4% | +7.3% | -20.2% | +9.4% | -4.0% | -0.8% | +15.7% | -15.0% | -9.1% | +2.6% | -0.7% | +10.1% |
| YoY Change | — | — | — | — | +34.7% | +40.9% | -1.0% | -11.3% | -39.8% | -52.9% | -20.7% | -2.3% | -5.0% | -14.2% | +19.9% | -1.7% | -6.7% | -3.1% | -23.1% | +3.8% |